胆囊癌复发模式及复发后生存预测。

IF 2.4 3区 医学 Q3 GASTROENTEROLOGY & HEPATOLOGY Journal of Gastrointestinal Surgery Pub Date : 2025-04-01 Epub Date: 2025-02-17 DOI:10.1016/j.gassur.2025.101997
Giovanni Catalano , Laura Alaimo , Odysseas P. Chatzipanagiotou , Zayed Rashid , Jun Kawashima , Andrea Ruzzenente , Federico Aucejo , Hugo P. Marques , Joao Bandovas , Tom Hugh , Nazim Bhimani , Shishir K. Maithel , Minoru Kitago , Itaru Endo , Timothy M. Pawlik
{"title":"胆囊癌复发模式及复发后生存预测。","authors":"Giovanni Catalano ,&nbsp;Laura Alaimo ,&nbsp;Odysseas P. Chatzipanagiotou ,&nbsp;Zayed Rashid ,&nbsp;Jun Kawashima ,&nbsp;Andrea Ruzzenente ,&nbsp;Federico Aucejo ,&nbsp;Hugo P. Marques ,&nbsp;Joao Bandovas ,&nbsp;Tom Hugh ,&nbsp;Nazim Bhimani ,&nbsp;Shishir K. Maithel ,&nbsp;Minoru Kitago ,&nbsp;Itaru Endo ,&nbsp;Timothy M. Pawlik","doi":"10.1016/j.gassur.2025.101997","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Gallbladder cancer (GBC) is associated with a poor prognosis. Recurrence patterns and their effect on survival remain ill-defined. This study aimed to analyze recurrence patterns and develop a machine learning (ML) model to predict survival after recurrence (SAR) of GBC.</div></div><div><h3>Methods</h3><div>Patients who underwent curative-intent resection of GBC between 1999 and 2022 were identified using an international database. An Extreme Gradient Boosting ML model to predict SAR was developed and validated.</div></div><div><h3>Results</h3><div>Among 348 patients, 110 (31.6%) developed disease recurrence during follow-up. The most common recurrence site was local (29.1%), followed by multiple site (26.4%), liver (21.8%), peritoneal (18.2%), and lung (0.05%). The median SAR was the longest in patients with lung recurrence (36.0 months), followed by those with local recurrence (15.7 months). In contrast, patients with peritoneal (8.9 months), liver (8.5 months), or multiple-site (6.4 months) recurrence had a considerably shorter SAR. Patients with multiple-site recurrence had a worse SAR than individuals with single-site recurrence (6.4 vs 11.10 months, respectively; <em>P</em> =.014). The model demonstrated good performance in the evaluation and bootstrapping cohorts (area under the receiver operating characteristic curve: 71.4 and 71.0, respectively). The most influential variables were American Society of Anesthesiologists classification, local recurrence, receipt of adjuvant chemotherapy, American Joint Committee on Cancer T and N categories, and developing early disease recurrence (&lt;12 months). To enable clinical applicability, an easy-to-use calculator was made available (<span><span>https://catalano-giovanni.shinyapps.io/SARGB</span><svg><path></path></svg></span>).</div></div><div><h3>Conclusion</h3><div>Except for lung recurrence, SAR for GBC was poor. A subset of patients with less aggressive disease biology may have favorable SAR. ML-based SAR prediction may help individuate candidates for curative re-resection when feasible.</div></div>","PeriodicalId":15893,"journal":{"name":"Journal of Gastrointestinal Surgery","volume":"29 4","pages":"Article 101997"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recurrence patterns and prediction of survival after recurrence for gallbladder cancer\",\"authors\":\"Giovanni Catalano ,&nbsp;Laura Alaimo ,&nbsp;Odysseas P. Chatzipanagiotou ,&nbsp;Zayed Rashid ,&nbsp;Jun Kawashima ,&nbsp;Andrea Ruzzenente ,&nbsp;Federico Aucejo ,&nbsp;Hugo P. Marques ,&nbsp;Joao Bandovas ,&nbsp;Tom Hugh ,&nbsp;Nazim Bhimani ,&nbsp;Shishir K. Maithel ,&nbsp;Minoru Kitago ,&nbsp;Itaru Endo ,&nbsp;Timothy M. Pawlik\",\"doi\":\"10.1016/j.gassur.2025.101997\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Gallbladder cancer (GBC) is associated with a poor prognosis. Recurrence patterns and their effect on survival remain ill-defined. This study aimed to analyze recurrence patterns and develop a machine learning (ML) model to predict survival after recurrence (SAR) of GBC.</div></div><div><h3>Methods</h3><div>Patients who underwent curative-intent resection of GBC between 1999 and 2022 were identified using an international database. An Extreme Gradient Boosting ML model to predict SAR was developed and validated.</div></div><div><h3>Results</h3><div>Among 348 patients, 110 (31.6%) developed disease recurrence during follow-up. The most common recurrence site was local (29.1%), followed by multiple site (26.4%), liver (21.8%), peritoneal (18.2%), and lung (0.05%). The median SAR was the longest in patients with lung recurrence (36.0 months), followed by those with local recurrence (15.7 months). In contrast, patients with peritoneal (8.9 months), liver (8.5 months), or multiple-site (6.4 months) recurrence had a considerably shorter SAR. Patients with multiple-site recurrence had a worse SAR than individuals with single-site recurrence (6.4 vs 11.10 months, respectively; <em>P</em> =.014). The model demonstrated good performance in the evaluation and bootstrapping cohorts (area under the receiver operating characteristic curve: 71.4 and 71.0, respectively). The most influential variables were American Society of Anesthesiologists classification, local recurrence, receipt of adjuvant chemotherapy, American Joint Committee on Cancer T and N categories, and developing early disease recurrence (&lt;12 months). To enable clinical applicability, an easy-to-use calculator was made available (<span><span>https://catalano-giovanni.shinyapps.io/SARGB</span><svg><path></path></svg></span>).</div></div><div><h3>Conclusion</h3><div>Except for lung recurrence, SAR for GBC was poor. A subset of patients with less aggressive disease biology may have favorable SAR. ML-based SAR prediction may help individuate candidates for curative re-resection when feasible.</div></div>\",\"PeriodicalId\":15893,\"journal\":{\"name\":\"Journal of Gastrointestinal Surgery\",\"volume\":\"29 4\",\"pages\":\"Article 101997\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Gastrointestinal Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1091255X25000563\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/2/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Surgery","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1091255X25000563","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/17 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:胆囊癌(GBC)预后较差。复发模式及其对生存的影响仍不明确。我们试图分析复发模式,并开发一种机器学习(ML)模型来预测GBC复发后的生存(SAR)。方法:在这项队列研究中,使用国际数据库确定1999年至2022年间接受治疗性GBC切除术的患者。开发并验证了用于预测SAR的XGBoost (Extreme Gradient-Boosting) ml模型。结果:348例患者中,110例(31.6%)在随访期间出现疾病复发。最常见的复发部位是局部(29.1%),其次是多部位(26.4%)、肝脏(21.8%)、腹膜(18.2%)和肺部(0.05%)。肺复发患者的平均生存期最长(36.0个月),其次是局部复发患者(15.7个月);相比之下,腹膜(8.9个月)、肝脏(8.5个月)和多部位复发(6.4个月)患者的SAR明显较短。值得注意的是,多部位复发患者的SAR明显较差(分别为6.43个月和11.10个月;p = 0.014)。该模型在评价和bootstrapping队列中表现良好(AUC分别为71.4和71.0)。影响最大的变量为ASA (American Society of Anesthesiologists)分级、局部复发、是否接受辅助化疗、AJCC (American Joint Committee on Cancer) T和N分类、是否出现早期疾病复发(结论:除肺部复发外,GBC的SAR较差。一小部分侵袭性较小的患者可能具有良好的SAR。基于ml的SAR预测可能有助于在可行的情况下个体化治疗性再切除的候选人。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Recurrence patterns and prediction of survival after recurrence for gallbladder cancer

Background

Gallbladder cancer (GBC) is associated with a poor prognosis. Recurrence patterns and their effect on survival remain ill-defined. This study aimed to analyze recurrence patterns and develop a machine learning (ML) model to predict survival after recurrence (SAR) of GBC.

Methods

Patients who underwent curative-intent resection of GBC between 1999 and 2022 were identified using an international database. An Extreme Gradient Boosting ML model to predict SAR was developed and validated.

Results

Among 348 patients, 110 (31.6%) developed disease recurrence during follow-up. The most common recurrence site was local (29.1%), followed by multiple site (26.4%), liver (21.8%), peritoneal (18.2%), and lung (0.05%). The median SAR was the longest in patients with lung recurrence (36.0 months), followed by those with local recurrence (15.7 months). In contrast, patients with peritoneal (8.9 months), liver (8.5 months), or multiple-site (6.4 months) recurrence had a considerably shorter SAR. Patients with multiple-site recurrence had a worse SAR than individuals with single-site recurrence (6.4 vs 11.10 months, respectively; P =.014). The model demonstrated good performance in the evaluation and bootstrapping cohorts (area under the receiver operating characteristic curve: 71.4 and 71.0, respectively). The most influential variables were American Society of Anesthesiologists classification, local recurrence, receipt of adjuvant chemotherapy, American Joint Committee on Cancer T and N categories, and developing early disease recurrence (<12 months). To enable clinical applicability, an easy-to-use calculator was made available (https://catalano-giovanni.shinyapps.io/SARGB).

Conclusion

Except for lung recurrence, SAR for GBC was poor. A subset of patients with less aggressive disease biology may have favorable SAR. ML-based SAR prediction may help individuate candidates for curative re-resection when feasible.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.50
自引率
3.10%
发文量
319
审稿时长
2 months
期刊介绍: The Journal of Gastrointestinal Surgery is a scholarly, peer-reviewed journal that updates the surgeon on the latest developments in gastrointestinal surgery. The journal includes original articles on surgery of the digestive tract; gastrointestinal images; "How I Do It" articles, subject reviews, book reports, editorial columns, the SSAT Presidential Address, articles by a guest orator, symposia, letters, results of conferences and more. This is the official publication of the Society for Surgery of the Alimentary Tract. The journal functions as an outstanding forum for continuing education in surgery and diseases of the gastrointestinal tract.
期刊最新文献
Employment disruption and missed workdays after neoadjuvant therapy receipt for high-risk gastrointestinal cancer Assessment of stapled vs handsewn anastomoses in video-assisted thoracoscopic and laparoscopic McKeown esophagectomy for esophageal cancer Letter to the editor regarding “Elevated early recurrence of paraesophageal hernias in chronic obstructive pulmonary disease patients: a comparative risk analysis” Letter to the editor regarding “The generalizability of outcomes after pancreatic resection for secondary tumors” Development of a novel priorities assessment tool to support shared decision-making in rectal cancer patients undergoing restorative proctectomy: a pilot study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1